Canada: Pharma Business Deal Therapure Biomanufacturing, VBI to Manufacture Coronavirus Vaccine Candidates
Under the manufacturing contract, Therapure will be responsible for the biomanufacturing of the vaccine drug substance and the aseptic fill of the drug product at Therapure’s Ontario facility in Canada.
Ontario/Canada – Therapure Biomanufacturing has recently announced the signing of an agreement with VBI Vaccines for the manufacture of their coronavirus vaccine candidates. Therapure Biomanufacturing is an integrated contract development and manufacturing organisation (CDMO) focused on biologic and high value therapeutics that can provide new options for patient care. Under this agreement, Therapure will be responsible for the biomanufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at the Therapure facility in Mississauga, Ontario.
Safa’a Al-Rais, Therapure’s Chief Operating Officer, said: “We are delighted to partner with VBI to assist us with providing an effective response to the ongoing Covid-19 pandemic through Therapure’s biomanufacturing and aseptic fill finish services for VBI’s innovative Covid-19 vaccine candidates, which utilise their flexible enveloped virus-like particle (eVLP) platform technology. Therapure prides itself on its development, clinical and commercial cGMP manufacturing expertise providing solutions for biologic therapeutics and innovative drug delivery technologies, which make a difference in patients’ lives.”
“We look forward to working with Therapure to address the ongoing public health challenge,” said Jeff Baxter, VBI’s President and CEO. “Therapure’s proven cGMP biomanufacturing capabilities and expertise with aseptic fill finish make them a great partner as we advance our vaccine candidate into and through clinical studies.”